文献速递甲状腺疾病

分化型甲状腺癌患者血清促甲状腺激素与癌症复发之间的关联:一项基于人群的回顾性队列研究

Association Between Serum Thyrotropin and Cancer Recurrence in Differentiated Thyroid Cancer: A Population-Based Retrospective Cohort Study.
PubMed 文献 · Thyroid · 2024-12-26

该研究基于加拿大安大略省行政健康数据库,纳入2007至2018年接受甲状腺切除术的分化型甲状腺癌患者26,336例,评估不同血清促甲状腺激素(TSH)目标范围与癌症复发的关联。结论认为低危分化型甲状腺癌患者维持TSH 0.5-2 mIU/L与2-4 mIU/L在临床显著复发上无差异。

要点

  • 低危分化型甲状腺癌患者维持TSH 0.5-2 mIU/L与2-4 mIU/L相比,临床显著复发无差异。

核心结论

  • 低危分化型甲状腺癌患者维持TSH 0.5-2 mIU/L与2-4 mIU/L相比,临床显著复发无差异。
  • 指南应考虑放宽低危队列甲状腺切除术后TSH目标水平。
  • 这些结果不能应用于高危分化型甲状腺癌患者。

研究设计与样本

  • 基于人群的回顾性队列研究,使用加拿大安大略省关联的行政健康数据库,随访2007至2018年甲状腺切除术后分化型甲状腺癌患者。
  • 暴露为时间更新的血清TSH,作为累积和瞬时暴露处理。
  • 采用多变量病因特异性比例风险回归分析,从索引日期起计算至分化型甲状腺癌复发时间,复发定义为再次颈部手术、放射性碘治疗和/或分化型甲状腺癌特异性死亡的复合终点。
  • 敏感性分析按初始治疗分层作为基线复发风险标志。
  • 队列共26,336例分化型甲状腺癌患者(78%女性),中位年龄50岁,中位随访5.9年(四分位距3.6-8.6年);40.9%仅初始接受半甲状腺切除术,38.2%接受全甲状腺切除加放射性碘治疗。

主要发现

  • 结果在各基线治疗组间相似。

临床怎么用

  • 作者认为指南应考虑放宽低危队列甲状腺切除术后TSH目标水平。
  • 这些结果不能应用于高危分化型甲状腺癌患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Levothyroxine to suppress thyrotropin (TSH) to <0.5 mIU/L following thyroidectomy in differentiated thyroid cancer (DTC) may reduce recurrence in higher-risk DTC. However, there is limited evidence to support guideline recommendations to maintain TSH in the low-normal range of 0.5-2 mIU/L to reduce recurrence in patients with lower risk DTC. The primary objective was to assess the association between exposure to high normal serum TSH (2-4 mIU/L) as compared with low normal TSH (0.5-2 mIU/L) target ranges and cancer recurrence in patients with DTC after thyroidectomy. Methods: This population-based retrospective cohort study used linked, administrative health care databases from Ontario, Canada, to follow patients with DTC post-thyroidectomy from 2007 to 2018. The exposure was time updated, serum TSH, treated as a cumulative and instantaneous exposure. Multivariable cause-specific proportional hazard regression analyses were performed to determine time to DTC recurrence from index date, defined as a composite of repeat neck surgery, radioactive iodine (RAI) treatment, and/or DTC-specific death. Results were also stratified by initial treatment as a marker of baseline recurrence risk in a sensitivity analysis. Results: This cohort of 26,336 individuals (78% female) with DTC and a median age of 50 years were followed for a median of 5.9 (interquartile range 3.6-8.6) years; 40.9% were initially treated with a hemi-thyroidectomy only and 38.2% received a total thyroidectomy and RAI. Compared with exposure to TSH 0.5 to ≤2 mIU/L, DTC recurrence rate was similar for each additional 3 months of exposure to TSH >2 to ≤4 mIU/L (adjusted cause specific [cs] hazard ratio [HR] 0.99 [confidence interval or CI 0.97-1.02]) but was significantly increased with each additional 3 months of exposure to TSH >4 mIU/L (adjusted csHR 1.07 [CI 1.04-1.09]). Results were similar across baseline treatment groups. Conclusion: There was no difference in clinically significant recurrence in those with low-risk DTC maintained with a TSH of 0.5-2 mIU/L compared with 2-4 mIU/L. Guidelines should consider liberalizing target TSH level post thyroidectomy in low-risk cohorts. These results cannot be applied to patients with high-risk DTC.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Qiang JK, Sutradhar R, Everett K, et al. Association Between Serum Thyrotropin and Cancer Recurrence in Differentiated Thyroid Cancer: A Population-Based Retrospective Cohort Study. Thyroid. 2024. PMID: 39723994. doi:10.1089/thy.2024.0330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。